Biosergen
10.10 SEK
0.00 %
Less than 1K followers
BIOSGN
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
0.00 %
-72.10 %
-76.51 %
-74.44 %
-79.22 %
-66.22 %
-84.75 %
-
-97.27 %
Biosergen is active in biotechnology. The company specializes in the research and development of antifungal drugs. The product portfolio includes, for example, an antifungal drug for the treatment of invasive fungal infections in immunosuppressed patients. The company collaborates with research institutes and pharmaceutical companies internationally. Biosergen was founded in 2004 and is headquartered in Solna.
Read moreMarket cap
23.72M SEK
Turnover
10.29K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20.5
2026
Interim report Q1'26
30.6
2026
General meeting '26
19.8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Biosergen AB: Biosergen Pauses Development of BSG005
Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools